Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Instil Bio (TIL) reported a third-quarter 2026 net loss of $4.2 million, narrowing from the corrected year-earlier loss. Loss per share was $0.62 versus $2.01, while nine-month net loss narrowed to $13.0 million from $63.5 million. Quarterly research and development expenses fell to $0.2 million from $9.1 million; general and administrative expenses declined to $5.8 million from $6.3 million.
Cash, restricted cash and investments totaled $67.1 million at September 30, 2026, versus $76.3 million at December 31, 2025. Instil expects these resources to fund its operating plan through 2027 and plans to build asset-focused subsidiaries through internal development or licensing. Prior-period figures were corrected for property-tax, tenant-reimbursement presentation and other immaterial errors; no prior filing is being amended.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter net loss narrowed to $4.231 million, or $0.62 per share, from $13.587 million, or $2.01, year over year.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Instil expects September 30, 2026 cash and investments to fund its operating plan through 2027.
- Minor pointNine-month net loss narrowed to $13.023 million, or $1.92 per share, from $63.495 million, or $9.58, year over year.
- Minor point. Forward-looking: it has not happened yet and may not happen.Instil plans asset-focused development subsidiaries, building candidates through internal development or licensing.
- Minor pointThird-quarter research and development expenses fell to $233,000 from $9.127 million year over year.
9 minor points
- Minor pointNine-month research and development expenses fell to $1.172 million from $21.241 million year over year.
- Minor pointNine-month in-process research and development expenses fell to nil from $10 million year over year.
- Minor pointThird-quarter general and administrative expenses declined to $5.833 million from $6.344 million year over year.
- Minor pointNine-month general and administrative expenses declined to $17.510 million from $22.689 million year over year.
- Minor pointThird-quarter restructuring and impairment costs became an $81,000 reversal, versus nil a year earlier.
- Minor pointNine-month restructuring and impairment charges declined to $1.092 million from $16.622 million year over year.
- Minor pointNine-month contract termination gain was $1.620 million, versus none a year earlier.
- Minor pointThird-quarter interest expense declined to $1.554 million from $1.582 million year over year.
- Minor pointRental income rose to $2.697 million quarterly and $8.090 million year-to-date, from $2.691 million and $8.076 million.
Negative
- Moderate pointCash, restricted cash and investments declined to $67.091 million at September 30, 2026, from $76.295 million at year-end 2025.
- Minor pointStockholders’ equity declined to $102.564 million at September 30, 2026, from $112.671 million at year-end 2025.
- Minor pointTotal liabilities increased to $93.081 million at September 30, 2026, from $91.844 million at year-end 2025.
- Minor pointTotal assets declined to $195.645 million at September 30, 2026, from $204.515 million at year-end 2025.
- Minor pointThird-quarter interest income fell to $615,000 from $893,000 year over year.
3 minor points
- Minor pointNine-month interest income fell to $1.925 million from $3.112 million year over year.
- Minor pointNine-month interest expense increased to $4.688 million from $4.398 million year over year.
- Minor pointNine-month other income of $267,000 became other expense of $196,000 year over year.
Key Figures
- Cash and investments
- $67.1 million
- As of September 30, 2026; expected to fund the current operating plan through 2027
- Net loss
- $4.2 million vs. $13.6 million
- Three months ended September 30, 2026 vs. 2025; 2025 amount as corrected
- Net loss
- $13.0 million vs. $63.5 million
- Nine months ended September 30, 2026 vs. 2025; 2025 amount as corrected
- Net loss per share
- $0.62 vs. $2.01
- Basic and diluted, three months ended September 30, 2026 vs. 2025; 2025 amount as corrected
- Non-GAAP net loss per share
- $0.48 vs. $1.75
- Basic and diluted, three months ended September 30, 2026 vs. 2025; 2025 amount as corrected
Previous Earnings Reports
-
Q2 loss narrowed and expenses fell; cash resources were expected to fund operations beyond 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
gaap financial
marketable securities financial
stock-based compensation financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs, today reported its third quarter 2026 financial results and provided a corporate update.
Recent Highlights:
- Asset-Focused Development Model: By combining focused and experienced teams with strategic support from Instil, Instil intends to establish a portfolio of asset-focused development subsidiaries. To accomplish this strategy, Instil intends to internally develop or in-license programs, building a diversified portfolio of development candidates.
- Cash Position: Cash, cash equivalents, restricted cash, marketable securities and long-term investments totaled approximately
$67.1 million as of September 30, 2026, which Instil expects will fund its current operating plan through 2027.
Third Quarter 2026 Financial and Operating Results:
As of September 30, 2026, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of
In-process research and development expenses were nil for the three and nine months ended September 30, 2026, compared to nil and
Research and development expenses were
General and administrative expenses were
Restructuring and impairment charges, net were a reversal of costs of
Net loss was
In preparing its third-quarter 2026 financial statements, Instil identified errors in previously issued financial statements relating to property taxes on its Tarzana, California facility and the presentation of amounts reimbursed by the facility’s tenant, as well as certain other immaterial errors. The errors were not material to any previously issued financial statements, and no prior filing is being amended. Instil has corrected the prior-period information in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and the 2025 amounts in this release are presented as corrected.
Note Regarding Use of Non-GAAP Financial Measures
In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges, net. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil’s financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil’s operating results. In addition, these non-GAAP financial measures are among the indicators Instil’s management uses for planning purposes and to measure Instil’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.
About Instil Bio
Instil Bio, Inc. is a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs. For more information, visit www.instilbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “exploring,” “evaluating,” “focused,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “targets,” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements concerning Instil’s expectations regarding establishing a portfolio of asset-focused development subsidiaries, internally developing or in-licensing programs, and building a diversified portfolio of development candidates; Instil’s expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties related to pursuing potential transactions to acquire companies or equity interests therein or in-license product candidates, and the sufficiency of Instil’s cash resources, as well as interest rates, inflation and other macroeconomic factors which could materially and adversely affect Instil’s business and operations, and other risks and uncertainties affecting Instil’s plans and strategy, including those discussed in the section titled “Risk Factors” in Instil’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the SEC and Instil ’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 27, 2026, as well as Instil’s other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.
Contacts:
Investor Relations:
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com
Media Relations:
Kimberly Ha
KKH Advisors
1-917-291-5744
kimberly.ha@kkhadvisors.com
| INSTIL BIO, INC. SELECTED FINANCIAL DATA | |||||
| Selected Condensed Consolidated Balance Sheet Data (Unaudited; in thousands) | |||||
| September 30, 2026 | December 31, 2025 | ||||
| Cash, cash equivalents, restricted cash, marketable securities and long-term investments | $ | 67,091 | $ | 76,295 | |
| Total assets | $ | 195,645 | $ | 204,515 | |
| Total liabilities | $ | 93,081 | $ | 91,844 | |
| Total stockholders’ equity | $ | 102,564 | $ | 112,671 | |
| Condensed Consolidated Statements of Operations (Unaudited; in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses: | |||||||||||||||
| In-process research and development | $ | — | $ | — | $ | — | $ | 10,000 | |||||||
| Research and development | 233 | 9,127 | 1,172 | 21,241 | |||||||||||
| General and administrative | 5,833 | 6,344 | 17,510 | 22,689 | |||||||||||
| Restructuring and impairment charges, net | (81 | ) | — | 1,092 | 16,622 | ||||||||||
| Total operating expenses | 5,985 | 15,471 | 19,774 | 70,552 | |||||||||||
| Loss from operations | (5,985 | ) | (15,471 | ) | (19,774 | ) | (70,552 | ) | |||||||
| Interest income | 615 | 893 | 1,925 | 3,112 | |||||||||||
| Interest expense | (1,554 | ) | (1,582 | ) | (4,688 | ) | (4,398 | ) | |||||||
| Other rental income | 2,697 | 2,691 | 8,090 | 8,076 | |||||||||||
| Gain on contract termination | — | — | 1,620 | — | |||||||||||
| Other (expense) income, net | (4 | ) | (118 | ) | (196 | ) | 267 | ||||||||
| Net loss | $ | (4,231 | ) | $ | (13,587 | ) | $ | (13,023 | ) | $ | (63,495 | ) | |||
| Net loss per share, basic and diluted | $ | (0.62 | ) | $ | (2.01 | ) | $ | (1.92 | ) | $ | (9.58 | ) | |||
| Weighted-average shares used in computing net loss per share, basic and diluted | 6,781,976 | 6,757,742 | 6,781,976 | 6,629,949 | |||||||||||
| INSTIL BIO, INC. Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss per Share (Unaudited; in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net loss | $ | (4,231 | ) | $ | (13,587 | ) | $ | (13,023 | ) | $ | (63,495 | ) | |||
| Adjustments: | |||||||||||||||
| Non-cash stock-based compensation expense | 984 | 1,768 | 3,005 | 7,087 | |||||||||||
| Restructuring and impairment charges, net | (81 | ) | — | 1,092 | 16,622 | ||||||||||
| Non-GAAP net loss | $ | (3,328 | ) | $ | (11,819 | ) | $ | (8,926 | ) | $ | (39,786 | ) | |||
| Net loss per share, basic and diluted | $ | (0.62 | ) | $ | (2.01 | ) | $ | (1.92 | ) | $ | (9.58 | ) | |||
| Adjustments: | |||||||||||||||
| Non-cash stock-based compensation expense per share | 0.15 | 0.26 | 0.44 | 1.07 | |||||||||||
| Restructuring and impairment charges, net per share | (0.01 | ) | — | 0.16 | 2.51 | ||||||||||
| Non-GAAP net loss per share, basic and diluted* | $ | (0.48 | ) | $ | (1.75 | ) | $ | (1.32 | ) | $ | (6.00 | ) | |||
| Weighted-average shares outstanding, basic and diluted | 6,781,976 | 6,757,742 | 6,781,976 | 6,629,949 | |||||||||||
* Non-GAAP net loss per share, basic and diluted may not total due to rounding.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Instil Bio’s third-quarter 2026 earnings results?
Instil Bio reported a net loss of $4.231 million, or $0.62 per basic and diluted share, compared with a corrected loss of $13.587 million, or $2.01 per share, in the third quarter of 2025.
How long does Instil Bio expect its September 2026 cash and investments to last?
Instil Bio expects its September 30, 2026 cash, cash equivalents, restricted cash, marketable securities and long-term investments to fund its operating plan through 2027. These resources totaled approximately $67.1 million.
What does Instil Bio exclude from its non-GAAP loss figures?
Instil Bio excludes non-cash stock-based compensation and restructuring and impairment charges, net, from its non-GAAP loss measures. Third-quarter 2026 non-GAAP net loss was $3.328 million, or $0.48 per share, compared with $11.819 million, or $1.75 per share, a year earlier. These measures supplement rather than replace GAAP results.